The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?

Cardiovascular Drugs and Therapy - Netherlands
doi 10.1007/s10557-014-6521-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Effects of Currently Prescribed LDL-C-lowering Drugs on PCSK9 and Implications for the Next Generation of LDL-C-lowering Agents

Lipids in Health and Disease
BiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2011English

Medicinal Chemistry of Novel Anti-Diabetic Drugs

Open Medicinal Chemistry Journal
Drug DiscoveryMolecular MedicinePharmacologyPharmaceutical Science
2011English

Joint Effects of Diabetic-Related Genomic Loci on the Therapeutic Efficacy of Oral Anti-Diabetic Drugs in Chinese Type 2 Diabetes Patients

Scientific Reports
Multidisciplinary
2016English

Repurposing Diabetes Drugs for Neurodegenerative Diseases: Anti-Diabetic Drug Reposition

International Research Journal Of Pharmacy
2019English

Prognostic Role of Anti-Diabetic Drugs in Pancreatic Cancer: A Systematic Review and Meta-Analysis

Oncotarget
Oncology
2019English

Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial

PLoS ONE
Multidisciplinary
2014English

Ocular Anti-Vegf Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2014English

The Cost of New Oral Anti-Diabetic Drugs in Canada and Internationally

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Commentary: Advances in the Pharmacotherapy of NASH-anti-diabetic Drugs and Beyond

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy